Cancer organoid co-culture model system: Novel approach to guide precision medicine

Front Immunol. 2023 Jan 12:13:1061388. doi: 10.3389/fimmu.2022.1061388. eCollection 2022.

Abstract

Three-dimensional cancer organoids derived from self-organizing cancer stems are ex vivo miniatures of tumors that faithfully recapitulate their structure, distinctive cancer features, and genetic signatures. As novel tools, current cancer organoids have been well established and rapidly applied in drug testing, genome editing, and transplantation, with the ultimate aim of entering clinical practice for guiding personalized therapy. However, given that the lack of a tumor microenvironment, including immune cells and fibrous cells, is a major limitation of this emerging methodology, co-culture models inspire high hope for further application of this technology in cancer research. Co-culture of cancer organoids and immune cells or fibroblasts is available to investigate the tumor microenvironment, molecular interactions, and chimeric antigen receptor-engineered lymphocytes in cancer treatment. In light of the recent progress in cancer organoid co-culture models, it is only possible to recognize the advantages and drawbacks of this novel model to exploit its full potential. In this review, we summarize the recent advances in the application of cancer organoids and co-culture models and how they could be improved in the future to benefit cancer research, especially precision medicine.

Keywords: CAR-T cells; cancer organoids; cancer-associated fibroblasts; co-culture models; tumor microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coculture Techniques
  • Humans
  • Neoplasms* / pathology
  • Organoids
  • Precision Medicine* / methods
  • Tumor Microenvironment

Grants and funding

This research was supported by the National Natural Science Foundation of China (No.82272964; No.82002848; No.82003397), the CAMS Innovation Fund for Medical Sciences (CIFMS) (2021- I2M-C&T-B-054, 2021-I2M-C&T-B-053), the Capital Characterized Clinical Application Research Fund of Beijing Municipal Science and Technology Commission of China (No. Z171100001017210), Fundamental Research Funds for the Central Universities (No. 3332021097), Beijing Hope Run Special Fund of Cancer Foundation of China (No. LC2021A14).